NL-OMON25255Other不适用
A randomized, placebo-controlled, double blind trial to study the effects of vitamin K2 and arterial calcification in patients with type 2 diabetes
MC Utrecht0 个研究点目标入组 0 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Middle aged men and women ¡Ý 40 years.
- •- Diagnosed with type 2 diabetes.
排除标准
- •- Contra-indication for undergoing 18F-NaF PET/CT scan (pregnancy, breastfeeding, recent radiotherapy or chemotherapy).
- •- Subject underwent amputation.
研究者
相似试验
招募中
2 期
A randomized, placebo-controlled, double blind trial to study the effects of Etidronate on ectopic CALCIfication in FAhr*s Disease or syndrome.Fahr's diseaseprimary familial brain calcification10007963NL-OMON53560niversitair Medisch Centrum Utrecht98
已完成
2 期
A randomized, placebo-controlled, double blind trial to investigate whether vitamin K2 can influence ongoing calcium deposition in patients with type 2 diabetescardiovascular diseaseArterial calcification10003216NL-OMON45148niversitair Medisch Centrum Utrecht70
进行中（未招募）
1 期
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-000082-16-PLEsoCap AG42
进行中（未招募）
4 期
Can treatment with Cerebrolysin improve recovery after acute ischemic stroke?Radiologically confirmed acute ischemic stroke with onset within 72 hours prior to screeningCirculatory SystemAcute ischemic strokeISRCTN88122184The foundation for the study of neuroscience and neuroregeneration290
进行中（未招募）
1 期
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-000082-16-NLEsoCap AG42